Cagrilintide

Overview

Cagrilintide is a long-acting synthetic analog of amylin, the pancreatic peptide hormone co-secreted with insulin that contributes to satiety and gastric-emptying regulation. It is most studied in combination with Semaglutide (the co-formulation referenced in the literature as CagriSema), where the amylin and GLP-1 pathways are investigated for additive metabolic effects. As an investigational compound it is not an approved finished drug; the material supplied here is a research reagent only. Lyochem supplies Cagrilintide as a lyophilized powder characterized lot-by-lot: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS for identity, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer. Sequence verification by tandem MS is available on request and recommended at first-time qualification. For labs studying the amylin + GLP-1 combination, Lyochem supplies Cagrilintide and Semaglutide as separate characterized lots rather than a pre-mixed blend, so each can be confirmed against its own analytical packet before the buyer prepares the combination in-protocol. Fills run mg-scale; this is reference-grade research material, distinct from compounding-scale API supply.

Applications & buyer fit

Specifications

CAS

1415456-99-3

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 159-195 hours

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion content (acetate / TFA)
• Peptide content (% net peptide)
• Bacterial endotoxin (LAL) on request — in vivo workflows

Regulatory note

Investigational compound; not approved as a finished drug in any jurisdiction. Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations — not a finished dosage form and not labelled for human administration. Buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.

Selected literature

1. Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194.
2. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748.
3. Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
4. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647.
5. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659.
6. D'Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiol Rev. 2024;32(1):83-90.

Frequently asked questions